Actively Recruiting
Anti-CD25 rhMAb for aGVHD Prevention in High-Risk Adults Using the daGOAT Model
Led by Institute of Hematology & Blood Diseases Hospital, China · Updated on 2025-08-08
174
Participants Needed
1
Research Sites
95 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
To assess the efficacy and safety of using recombinant humanized anti-CD25 monoclonal antibody injection as a prophylactic strategy for reducing the incidence of severe acute graft-versus-host disease (aGVHD) in adult patients at intermediate to high risk, as predicted by the dynamic aGVHD Onset Anticipation Tianjin (daGOAT) model, following allogeneic hematopoietic stem cell transplantation (allo-HSCT).
CONDITIONS
Official Title
Anti-CD25 rhMAb for aGVHD Prevention in High-Risk Adults Using the daGOAT Model
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age ≥ 16 years, regardless of gender.
- Patients with hematologic disorders who are scheduled to receive allo-HSCT.
- Voluntarily join this study, sign the informed consent form, have good compliance, and be willing to cooperate with follow-up.
You will not qualify if you...
- Patients who have received a second or multiple transplants.
- Patients who are allergic to, or intolerant of, a recombinant humanized anti-CD25 monoclonal antibody injection.
- Pregnant or lactating female patients or female patients who are unable to take effective contraceptive measures during the entire trial period.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Institute of Hematology & Blood Diseases Hospital
Tianjin, Tianjin Municipality, China, 300020
Actively Recruiting
Research Team
E
erlie jiang
CONTACT
Y
yigeng cao
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
PREVENTION
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here